Home
Conditions
Lenvatinib

Clinical trial condition

Lenvatinib

Explore clinical trials studying Lenvatinib. Study availability and eligibility vary by location and protocol.

19 public trials 10 recruiting studies

Refine in advanced search Browse all conditions

Lenvatinib trial results

Not Yet Recruiting

Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial

NCT07514429

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
Locations: Asan Medical Center Seoul, South Korea

View Trial Details

Not Yet Recruiting

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

NCT07159217

Conditions: Biliary Tract Cancer, Biliary Tract Diseases, Biliary Tract Neoplasms, +7 more
Locations: Chinese Academy of Medical Sciences, Peking Union Medical College Hospital Beijing, China

View Trial Details

Not Yet Recruiting

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

NCT05286320

Conditions: Lenvatinib, Pembrolizumab, Stereotactic Body Radiotherapy, +1 more
Locations: National Taiwan University Hospital Taipei, Taiawn, Taiwan

View Trial Details

Completed

HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)

NCT06631326

Conditions: Adenocarcinoma, BCLC Stage C Hepatocellular Carcinoma, Carcinoma, +13 more
Locations: The first hospital of China medical university Shenyang, Liaoning, China

View Trial Details

Completed

Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC

NCT04791176

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +16 more
Locations: Bo Chen Beijing, Beijing Municipality, China

View Trial Details

Completed

Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC

NCT06435013

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
Locations: Cancer Center Sun Yat-sen University Guangzhou, Guangdong, China

View Trial Details

Active, Not Recruiting

Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging

NCT07581769

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +14 more
Locations: The First Affiiated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China

Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China

View Trial Details

Active, Not Recruiting

The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications.

NCT07233759

Conditions: Atezolizumab, Digestive System Diseases, Digestive System Neoplasms, +7 more
Locations: National Taiwan University Hospital Taipei, Taiwan

View Trial Details

Active, Not Recruiting

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

NCT04669496

Conditions: Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +7 more
Locations: Zhongshan hospital Shanghai, Shanghai Municipality, China

View Trial Details

Lenvatinib

Lenvatinib trial results

Related conditions